The tirzepatide SURMOUNT-1 trial, published in NEJM in 2022, is the largest and most rigorous obesity drug trial any incretin compound has produced. It's also the data that built Zepbound.
SURMOUNT-1 randomized 2,539 adults with obesity (BMI ≥30, or ≥27 with weight-related comorbidity) to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. At the highest dose, mean weight loss hit 22.5%. 91% reached at least 5% weight loss. 57% reached at least 20%. GI side effects matched the class: nausea 33%, diarrhea 22%, vomiting 12%, mostly mild-to-moderate during dose escalation. The follow-up SURMOUNT-4 trial showed discontinuation produces major weight regain, reframing tirzepatide as chronic therapy.
Before SURMOUNT-1, the obesity pharmacotherapy ceiling was 15% mean weight loss. That is what semaglutide established with STEP-1 in 2021. SURMOUNT-1's 22.5% represented a step change in what a single-molecule injectable had been shown to achieve in a Phase III trial. This article covers the trial design, the four arms, the tolerability profile, and what the SURMOUNT-4 maintenance trial added.
How was SURMOUNT-1 designed?
SURMOUNT-1 was a phase 3, double-blind, randomized, placebo-controlled trial conducted at 119 sites in 9 countries, led by Ania Jastreboff at Yale. The team randomized 2,539 adults in a 1:1:1:1 ratio to tirzepatide 5 mg, 10 mg, 15 mg, or placebo. Dosing was subcutaneous once weekly over 72 weeks, with lifestyle intervention across all arms.
Eligibility criteria:
- BMI ≥30 kg/m² — the primary obesity indication, or
- BMI ≥27 kg/m² with at least one weight-related comorbidity — hypertension, abnormal cholesterol, sleep apnea, or cardiovascular disease.
- No type 2 diabetes. Study participants with T2D were enrolled separately in SURMOUNT-2.
- Adults 18+ with stable weight for at least 3 months and at least one prior weight-loss attempt.
Dose titration was structured. Participants started at 2.5 mg weekly, then stepped up by 2.5 mg every four weeks to their assigned target dose. This titration schedule was subsequently adopted in the FDA-approved Zepbound prescribing information.
Co-primary endpoints were percent change in body weight at week 72 and the proportion of participants reaching at least 5% weight loss. Secondary endpoints included response thresholds at 10%, 15%, 20%, and 25%, plus changes in cardiometabolic risk factors.
Tirzepatide
The same compound cited across the 4 trials in this review. Lab-verified identity and purity.
What did the four arms actually show?
The headline weight-loss numbers at week 72:
- Tirzepatide 15 mg: −22.5% mean body weight change (highest-dose arm)
- Tirzepatide 10 mg: −21.4% mean body weight change
- Tirzepatide 5 mg: −16.0% mean body weight change
- Placebo: −2.4% mean body weight change
The dose-response curve is real, but it's compressing between 10 mg and 15 mg. That suggests tirzepatide is approaching its biological ceiling somewhere in the 15–20 mg range. The 5 mg arm still produces clinically meaningful weight loss. The 10 mg and 15 mg arms are within a few percentage points of each other, both well above the 5 mg ceiling.
Mean weight loss is one number. It does not capture variance inside an arm. The threshold-response data provides additional resolution on the distribution of outcomes. The proportion of study participants reaching each threshold at the 15 mg dose:
- ≥5% weight loss: 91% on tirzepatide 15 mg vs. 35% on placebo
- ≥10% weight loss: 84% on tirzepatide 15 mg vs. 19% on placebo
- ≥15% weight loss: 71% on tirzepatide 15 mg vs. 9% on placebo
- ≥20% weight loss: 57% on tirzepatide 15 mg vs. 3% on placebo
- ≥25% weight loss: 36% on tirzepatide 15 mg vs. 1.5% on placebo
The 57% reaching at least 20% weight loss has been noted in the literature as clinically significant. Prior research had associated weight-loss magnitudes in this range primarily with bariatric surgery outcomes; SURMOUNT-1 was the first Phase III drug trial to document a majority of study participants exceeding that threshold with a pharmacological agent.
What did the tolerability profile show?
Here's the part of any GLP-1-class trial worth reading honestly. Tolerability matched the established class. Roughly 60–80% of participants experienced at least one gastrointestinal adverse event, with most concentrated in the dose-escalation phase.
The most common GI events on the 15 mg dose:
- Nausea: approximately 33% of participants (vs. 10% on placebo)
- Diarrhoea: approximately 22% (vs. 9% placebo)
- Constipation: approximately 17% (vs. 6% placebo)
- Vomiting: approximately 12% (vs. 2% placebo)
- Abdominal pain: approximately 10%
Most events were mild-to-moderate and transient. Rates dropped significantly past dose titration. Severe events (grade 3+) occurred in roughly 3–5% of tirzepatide participants and were the primary driver of discontinuations. Treatment discontinuation due to adverse events occurred in approximately 4–7% of tirzepatide participants vs. 3% on placebo. That's a small but real tolerability cost.
The most common adverse events with tirzepatide were gastrointestinal — nausea, diarrhoea, vomiting, and constipation — mostly mild-to-moderate.
— Jastreboff et al., NEJM, 2022
In SURMOUNT-1, roughly two-thirds of study participants on tirzepatide reported at least mild GI adverse events in the dose-escalation phase. The majority remained on therapy as symptoms resolved. A small proportion required dose reduction or discontinuation. The trial authors noted that structured dose-titration management was associated with improved tolerability through the early treatment window.
What did SURMOUNT-4 add about maintenance?
SURMOUNT-4, published in JAMA in 2024, addressed the question SURMOUNT-1 couldn't answer: what happens when you stop?
Aronne and colleagues designed a randomized withdrawal trial. All participants received open-label tirzepatide for 36 weeks (the "lead-in" phase), during which mean weight loss was 20.9%. At week 36, the 670 participants who completed the lead-in were re-randomized 1:1 to continue tirzepatide or switch to placebo for another 52 weeks.
The result at week 88:
- Continued tirzepatide: additional −5.5% weight loss in the maintenance phase.
- Switched to placebo: +14.0% regain.
- Total weight change from baseline: −25.3% on continued tirzepatide vs. −9.9% on placebo.
- Maintained at least 80% of lead-in weight loss: 89.5% on continued tirzepatide vs. 16.6% on placebo.
SURMOUNT-4 reframed obesity pharmacotherapy: the trial demonstrated that tirzepatide's weight-reduction effects are not sustained after discontinuation. Study participants who switched to placebo regained approximately 80% of lost weight over 52 weeks. The authors concluded that the data support a chronic-maintenance framing for incretin therapy, with implications for treatment-duration planning and long-term durability assessments.
What did the cardiometabolic risk-factor data show?
Beyond the weight-loss numbers, SURMOUNT-1 also documented meaningful improvements in cardiometabolic risk factors across the tirzepatide arms:
- Systolic blood pressure: mean reduction of 7–8 mmHg on tirzepatide vs. 1 mmHg on placebo.
- Triglycerides: roughly 25–28% reduction on tirzepatide vs. modest change on placebo.
- HbA1c: mean reduction of 0.4–0.5% (in non-diabetic population — expected magnitudes are smaller than in T2D).
- Waist circumference: meaningful reductions paralleling the weight-loss magnitude.
- HOMA-IR (insulin sensitivity): substantial improvements.
These are the risk-factor improvements that predict downstream cardiovascular event reduction. The dedicated SURMOUNT-MMO cardiovascular outcomes trial is what would actually prove event reduction at scale, analogous to what SELECT did for semaglutide. That readout is still pending.
How does SURMOUNT-1 stack up against the rest of the field?
SURMOUNT-1 sits at the center of the obesity pharmacotherapy evidence base in 2026. Cross-trial comparisons (with the usual methodological caveats):
- Semaglutide 2.4 mg in STEP-1 (2021): 14.9% mean weight loss at 68 weeks.
- Tirzepatide 15 mg in SURMOUNT-1 (2022): 22.5% mean weight loss at 72 weeks.
- Retatrutide 12 mg in Phase II NEJM (2023): 24.2% mean weight loss at 48 weeks (Phase II only, n=338).
- CagriSema in REDEFINE-1 (2025): 20.4% mean weight loss at 68 weeks.
Tirzepatide's 22.5% remains the highest Phase III obesity result in published data. Retatrutide's 24.2% is nominally higher but from a Phase II trial; the Phase III TRIUMPH program will determine whether that magnitude holds at scale. CagriSema's 20.4% is Phase III data but lower in magnitude. The competitive landscape across dual- and triple-agonist programs remains active over the next 24 to 36 months.
Tirzepatide
39-aa dual GIP/GLP-1 agonist with C20 fatty-diacid acyl chain. The same reference compound used across the cited SURMOUNT and SURPASS trials. COA available with each lot.
What to know now
- Trial design: 2,539 adults, four arms (5 mg, 10 mg, 15 mg, placebo), 72 weeks, 9 countries.
- Headline result: 22.5% mean weight loss on tirzepatide 15 mg vs. 2.4% on placebo.
- Threshold response: 91% reached ≥5%, 71% reached ≥15%, 57% reached ≥20%, 36% reached ≥25% weight loss on 15 mg.
- Tolerability: GI adverse events ~60–80% in tirzepatide arms, mostly mild-to-moderate, primarily during dose titration; ~4–7% discontinuation rate.
- SURMOUNT-4 maintenance: 25.3% overall weight loss at week 88 with continued tirzepatide; 14% regain with placebo switch.
- Cardiometabolic benefits: meaningful improvements in BP, triglycerides, HbA1c, waist circumference, insulin sensitivity.
- Regulatory status: FDA-approved as Zepbound for obesity (November 2023); globally available.
What we’re watching
Four things over the next 18–24 months. First, the SURMOUNT-MMO cardiovascular outcomes readout — whether tirzepatide demonstrates SELECT-equivalent CV benefit. Second, retatrutide Phase III TRIUMPH results — whether 24.2% holds up at scale and pushes tirzepatide from category-leader to category-foundation. Third, oral incretin formulations (orforglipron and similar) progressing through Phase III — an oral GLP-1 or dual-agonist would change tirzepatide’s positioning in the prescribing algorithm. Fourth, multi-year durability data past 88 weeks — SURMOUNT-style follow-up at 3, 5, and 10 years is the next frontier.
References
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
- Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — A Phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972